Alkem inks licensing pact with Takeda to introduce Vonoprazan in India

Alkem Laboratories has entered into a patent licensing agreement with Takeda Pharmaceutical to market Vonoprazan in India. This medication is used to treat conditions like reflux esophagitis and various ulcers. This licensing deal will enhance Alkem's offerings in the gastrointestinal segment, according to CEO Vikas Gupta. The company's shares dropped 1.66% on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ulcrmtk
via IFTTT